Search Results - "Jongs, N"

POS-831 THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH eGFR <30 mL/min/1.73m2: FINDINGS FROM THE DAPA-CKD TRIAL by Chertow, G.M., Vart, P., Jongs, N., Toto, R.D., Gorriz, J.L., Hou, F.F., McMurray, J.J.V., Correa-Rotter, R., Rossing, P., Sjöström, C.D., Stefánsson, B.V., Langkilde, A.M., Wheeler, D.C., Lambers Heerspink, H.

Get full text

POS-832 DAPAGLIFLOZIN IN IgA NEPHROPATHY: FINDINGS FROM THE DAPA-CKD TRIAL by Lambers Heerspink, H., Toto, R.D., Jongs, N., Vart, P., Chertow, G.M., Hou, F.F., McMurray, J.J.V., Pecoits-Filho, R., Correa-Rotter, R., Rossing, P., Sjöström, C.D., Stefánsson, B.V., Umanath, K., Langkilde, A.M., Wheeler, D.C.

Get full text

Summary for Patients: Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease

Get full text

In CKD, the effect of dapagliflozin on kidney outcomes did not vary by T2DM status or CKD cause by Kohn, Orly F

“…Wheeler DC, Stefánsson BV, Jongs N, et al. Lancet Diabetes Endocrinol. 2021;9:22-31. 33338413…”
Get full text

The effects of dapagliflozin on kidney and cardiovascular outcomes in patients with chronic kidney disease with and without heart failure by Heerspink, J L, Wheeler, D C, Vart, P, Jongs, N, Hou, F F, Langkilde, A M, Correa-Rotter, R, Rossing, P, Sjostrom, C D, Toto, R D, Chertow, G M, Stefansson, B V, McMurray, J J V

“…Abstract Background Heart failure (HF) is highly prevalent in patients with chronic kidney disease (CKD) and the severity of kidney impairment increases risk…”
Get full text

Passive behavioural monitoring in neuropsychiatric disorders using smartphone technology by Jongs, N., Jagesar, R., Koning, I., Ruhe, H., Van Haren, N., Vorstman, J., Kas, M.

Get full text

P.4.004 - Passive behavioural monitoring in neuropsychiatric disorders using smartphone technology by Jongs, N., Jagesar, R., Koning, I., Ruhe, H., Van Haren, N., Vorstman, J., Kas, M.

“…The majority of medical disciplines utilize a measurement-based approach for the prevention and early detection of major medical events by monitoring measures…”
Get full text

A framework for assessing neuropsychiatric phenotypes by using smartphone-based location data by Jongs, Niels, Jagesar, Raj, van Haren, Neeltje E. M., Penninx, Brenda W. J. H., Reus, Lianne, Visser, Pieter J., van der Wee, Nic J. A., Koning, Ina M., Arango, Celso, Sommer, Iris E. C., Eijkemans, Marinus J. C., Vorstman, Jacob A., Kas, Martien J.

“…The use of smartphone-based location data to quantify behavior longitudinally and passively is rapidly gaining traction in neuropsychiatric research. However,…”
Get full text

POS-202 DAPAGLIFLOZIN IN PATIENTS WITH CHRONIC KIDNEY DISEASE TREATED WITH MINERALOCORTICOID RECEPTOR ANTAGONISTS: PRE-SPECIFIED ANALYSIS OF THE DAPA-CKD TRIAL by Provenzano, M., Jongs, N., Stefánsson, B.V., Chertow, G.M., Langkilde, A.M., McMurray, J.J., Correa-Rotter, R., Rossing, P., Sjöström, C.D., Toto, R.D., Wheeler, D.C., Lambers Heerspink, H.

Get full text

POS-831 THE EFFECT OF DAPAGLIFLOZIN IN PATIENTS WITH eGFR &lt;30 mL/min/1.73m2: FINDINGS FROM THE DAPA-CKD TRIAL by Chertow, G.M., Vart, P., Jongs, N., Toto, R.D., Gorriz, J.L., Hou, F.F., McMurray, J.J.V., Correa-Rotter, R., Rossing, P., Sjöström, C.D., Stefánsson, B.V., Langkilde, A.M., Wheeler, D.C., Lambers Heerspink, H.

Get full text